.jpg)
Ms. Chen is joining the Firm as a Senior Research Analyst and Managing Director, focused on Specialty Pharmaceuticals Equity Research. Mr. Ste ed is also joining as an Equity Research Analyst, focused on Medical Supplies & Devices . Both are reporting to Mara Goldstein, Director of Equity Research, and are based in New York.
"Against a backdrop of vigorous growth and innovation in the healthcare sector, Cantor Fitzgerald is further expanding its thought leadership, while providing value for clients in these complex and dynamic industries," said Shawn Matthews, CEO of Cantor Fitzgerald & Co.
Ms. Chen is joining the Firm from Guggenheim Securities, where she launched and led the Specialty Pharmaceuticals research vertical. Louise was previously at several leading firms, including Morgan Stanley.
Mr. Steed is joining the Firm from Bank of America Merrill Lynch where he was a Vice President in Equity Research, focusing on Medical Supplies & Devices.
"The addition of analysts of this caliber underscores Cantor's commitment to expanding the depth and breadth of its healthcare research team and to complementing its already highly respected healthcare research coverage," said Mara Goldstein. "I am confident that their deep industry knowledge and insights will add significant value for our clients." As recently as this winter, Cantor Fitzgerald added William Tanner, Ph.D. to its Biotechnology team and Steven Halper to its Healthcare Services team.
